AI-Assisted Precision Psychiatric Dosing System MindDose Enters Phase III: Antidepressant Side Effects Reduced by 60%

Digital health company BrainBridge announced on May 3 that its AI psychiatric medication dosing optimization system MindDose has officially launched Phase III multicenter clinical trials following Phase II completion. Phase II data showed MindDose reduced SSRI antidepressant side effect incidence from 67% with traditional "empirical titration" to 27%, while shortening the average time to reach effective therapeutic concentration from 6.2 weeks to 2.8 weeks.

MindDose integrates patient genomic data (particularly polymorphisms in drug metabolism enzymes like CYP2D6 and CYP2C19), weight, age, liver and kidney function indicators, and prior medication responses through a pharmacokinetic-pharmacodynamic (PK-PD) model to calculate optimal starting doses and titration schedules. The system dynamically adjusts subsequent doses based on patient self-reported symptoms during the first two weeks plus sleep and activity data from wearable devices.

Psychiatric medication has long been called "trial-and-error medicine" — doctors select drugs and doses based on experience, switching or adjusting if effects are inadequate or side effects too severe. This process is lengthy and painful for patients. Columbia University psychiatry professor Dr. Jonathan Alpert notes: "The trial-and-error process of psychiatric prescribing is itself a form of iatrogenic harm. If AI can shorten this process, the significance is enormous."

Phase III trials will recruit 2,400 patients with major depressive disorder across 32 hospitals in the US and Europe, with topline data expected by end of 2030. BrainBridge also disclosed that MindDose expansion studies for anxiety and bipolar disorder are in planning.